Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972876 | 0.84 | MEN1 (0.32) | MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL27082391 | 0.84 | MEN1 (0.32) | MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL30630824 | 0.84 | GCG (0.36) | RAB9A | |
| SCHEMBL24409267 | 0.84 | GCG (0.36) | RAB9A | |
| SCHEMBL29972943 | 0.82 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL27082322 | 0.82 | CYP11B1 (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL29973045 | 0.79 | KDM4E (0.35) | RAB9AKMT2A | |
| SCHEMBL27082404 | 0.79 | KDM4E (0.35) | RAB9AKMT2A | |
| SCHEMBL24409152 | 0.75 | DHODH (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL30630829 | 0.75 | DHODH (0.34) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | RAB9A 852/4885MEN1 25/4885KMT2A 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.